NZ334827A - High-capacity adenoviral vectors suitable for adenoviral-based gene therapy - Google Patents

High-capacity adenoviral vectors suitable for adenoviral-based gene therapy

Info

Publication number
NZ334827A
NZ334827A NZ334827A NZ33482797A NZ334827A NZ 334827 A NZ334827 A NZ 334827A NZ 334827 A NZ334827 A NZ 334827A NZ 33482797 A NZ33482797 A NZ 33482797A NZ 334827 A NZ334827 A NZ 334827A
Authority
NZ
New Zealand
Prior art keywords
polypeptide
encoding
dna sequence
plasmid
fibre
Prior art date
Application number
NZ334827A
Other languages
English (en)
Inventor
Glen R Nemerow
Seggern Daniel J Von
Original Assignee
Scripps Research Inst
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Novartis Ag filed Critical Scripps Research Inst
Priority to NZ508399A priority Critical patent/NZ508399A/xx
Publication of NZ334827A publication Critical patent/NZ334827A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Hybrid Cells (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
NZ334827A 1996-09-25 1997-09-24 High-capacity adenoviral vectors suitable for adenoviral-based gene therapy NZ334827A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ508399A NZ508399A (en) 1996-09-25 1997-09-24 Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71980696A 1996-09-25 1996-09-25
PCT/EP1997/005251 WO1998013499A2 (en) 1996-09-25 1997-09-24 Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors

Publications (1)

Publication Number Publication Date
NZ334827A true NZ334827A (en) 2001-02-23

Family

ID=24891439

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ334827A NZ334827A (en) 1996-09-25 1997-09-24 High-capacity adenoviral vectors suitable for adenoviral-based gene therapy
NZ508399A NZ508399A (en) 1996-09-25 1997-09-24 Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ508399A NZ508399A (en) 1996-09-25 1997-09-24 Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors

Country Status (9)

Country Link
EP (2) EP1471146B1 (enExample)
JP (2) JP4350800B2 (enExample)
AT (1) ATE420182T1 (enExample)
AU (1) AU4624197A (enExample)
CA (1) CA2266342C (enExample)
DE (1) DE69739211D1 (enExample)
IL (1) IL128958A0 (enExample)
NZ (2) NZ334827A (enExample)
WO (1) WO1998013499A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
CA2327444A1 (en) * 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
WO2000012740A2 (en) 1998-08-28 2000-03-09 Duke University ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU767975B2 (en) * 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
IT1302403B1 (it) * 1998-11-06 2000-09-05 Angeletti P Ist Richerche Bio Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1141357A1 (en) * 1999-01-14 2001-10-10 Novartis AG Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1124977A1 (fr) * 1999-08-27 2001-08-22 Transgene S.A. Fibre adenovirale modifiee et utilisations
AU1817401A (en) * 1999-12-14 2001-06-25 Genovo, Incorporated Methods and compositions for the manufacture of replication incompetent adenovirus
JP2003534805A (ja) * 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン 変化した親和性を有する改変ウシアデノウイルス
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US6946126B2 (en) * 2001-06-04 2005-09-20 Duke University Replicating adenovirus vectors
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
US7482156B2 (en) 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951138L (fi) * 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
CN1263864C (zh) * 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same

Also Published As

Publication number Publication date
WO1998013499A2 (en) 1998-04-02
ATE420182T1 (de) 2009-01-15
WO1998013499A3 (en) 1998-08-27
IL128958A0 (en) 2000-02-17
JP2009072205A (ja) 2009-04-09
EP1471146B1 (en) 2009-01-07
CA2266342C (en) 2010-06-08
NZ508399A (en) 2003-06-30
EP0937150A2 (en) 1999-08-25
DE69739211D1 (de) 2009-02-26
CA2266342A1 (en) 1998-04-02
EP1471146A3 (en) 2005-03-30
JP4350800B2 (ja) 2009-10-21
EP1471146A2 (en) 2004-10-27
AU4624197A (en) 1998-04-17
JP2001505047A (ja) 2001-04-17

Similar Documents

Publication Publication Date Title
NZ334827A (en) High-capacity adenoviral vectors suitable for adenoviral-based gene therapy
Legrand et al. Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber
CA2278616C (en) Adenoviruses having altered hexon proteins
Shinoura et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas
Louis et al. Cell-binding domain of adenovirus serotype 2 fiber
Yeh et al. Advances in adenoviral vectors: from genetic engineering to their biology
US6312699B1 (en) Ligands added to adenovirus fiber
Fallaux et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
Matsushita et al. Adeno-associated virus vectors can be efficiently produced without helper virus
Stevenson et al. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain
US5770442A (en) Chimeric adenoviral fiber protein and methods of using same
AU724189B2 (en) Vectors and methods for gene transfer to cells
EP1070118B1 (en) Modified adenovirus containing a fiber replacement protein
Shenk et al. Genetic analysis of adenoviruses
Jakubczak et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells
MXPA00012617A (es) Adenovirus recombinante con replicacion defectuosa con un promotor tardio principal mutado.
WO1995016048A3 (en) Recombinant protein production in bovine adenovirus expression vector system
HUP0200073A2 (hu) Célzott adenovírus vektorok heterológ gének beadására
CA2428739A1 (en) Complementing cell lines
Lusky et al. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3
WO1998050053A1 (en) Gene transfer with adenoviruses having modified fiber proteins
WO2003062400A9 (en) Fiber shaft modifications for efficient targeting
CA2228269A1 (en) High efficiency helper system for aav vector production
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
CA2378586A1 (en) Replication-competent anti-cancer vectors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)